Search
Close this search box.

European Hematology Association Hybrid Congress

EHA 2023

  1. ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
  2. Aptose Presents Highlights from Clinical Update
  3. AstraZeneca showcases scientific advances across rare and malignant haematological conditions
  4. BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline
  5. CARVYKTI (ciltacabtagene autoleucel; cilta-cel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
  6. Cellectis Presents Updated Clinical and Translational Data on BALLI-01 
  7. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas
  8. Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma, Highlighting 100% ORR
  9. Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD AML Patients
  10. HUTCHMED Highlights Presentations for Hematological Malignancy Programs
  11. Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML
  12. Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program
  13. Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib 
  14. Nkarta Presents NKX019 Clinical Data 
  15. Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120
  16. Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes

Share:

Read more